Novartis defends South Korean pricing of Glivec
This article was originally published in Scrip
Novartis has rebutted suggestions that it has resisted attempts to reduce the cost of its leukaemia drug Glivec (imatinib) in South Korea.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.